Manipal Hospitals’ IPO clears SEBI; Temasek calls listing an event, not an exit

Temasek reaffirmed long-term backing for Manipal Hospitals after SEBI approved the hospital chain’s proposed IPO, reportedly targeting a listing by end-July. The offering is expected to be near $1 billion at an estimated $8.3 billion valuation.

— Source publishedWed, 22 Jul, 2026, 18:07 IST·First seen Wed, 22 Jul, 2026, 19:16 IST·Source NDTV Profit

What happened

Temasek reaffirmed its long-term commitment to Manipal Hospitals after SEBI approved the hospital chain’s proposed IPO. The investor expects a listing by

Key facts

  • Proposed IPO expected to be close to $1 billion
  • Reported IPO valuation of $8.3 billion
  • Temasek plans to deploy approximately $10 billion in India over the next three years
  • Temasek invested in NSE in 2010

Why this matters

A public-market valuation near $8.3 billion would give Manipal Hospitals a stronger currency for acquisitions, partnerships and consolidation in India’s fragmented hospital sector.

What to watch

  • Draft/prospectus filing disclosures on revenue growth, EBITDA margins, net debt, capex commitments, contingent liabilities and acquisition-related goodwill.
  • Exact issue size, price band, implied enterprise value and split between primary capital raising and secondary shareholder sales.
  • Temasek's indicated post-listing stake, lock-up period, board rights and any language around future monetization.
  • Anchor-book quality, institutional subscription levels, retail demand and overall market volatility during bookbuilding.
  • Comparable public hospital valuation multiples, especially changes in Apollo Hospitals, Fortis Healthcare, Max Healthcare and other healthcare-services names.
  • Evidence of operating momentum: occupancy, bed additions, payer mix, doctor attrition, insurance receivable days and ARPOB trends.
  • Policy changes affecting health-insurance reimbursement, price controls, medical-tourism flows or hospital compliance costs.
  • Finalize red herring prospectus details, including fresh-issue versus offer-for-sale mix, use of proceeds, promoter and Temasek post-IPO ownership, and any lock-up arrangements.
  • Begin investor education emphasizing patient volumes, occupancy, ARPOB growth, specialty mix, margin expansion and the integration record of acquired hospital assets.
  • Use IPO proceeds and public equity currency to accelerate brownfield capacity additions, selective acquisitions and expansion in underpenetrated tier-2 and tier-3 cities.
  • Competitors and private-equity-backed hospital chains may revisit IPO, stake-sale or fundraising plans if Manipal establishes a strong valuation benchmark.
  • Large strategic shareholders may retain stakes but gradually diversify through future block trades if the listing produces sustained liquidity and premium valuation.